These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38741823)

  • 41. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proximal Left Main Coronary Artery Aneurysm Presenting as ST-Elevation Myocardial Infarction Treated by Stenting.
    Vinod VC; Yousif ZE; Salim NO; Majwal T
    Case Rep Cardiol; 2020; 2020():8833917. PubMed ID: 33204540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Harrington RA; Becker RC; Cannon CP; Gutterman D; Lincoff AM; Popma JJ; Steg G; Guyatt GH; Goodman SG
    Chest; 2008 Jun; 133(6 Suppl):670S-707S. PubMed ID: 18574276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
    Hu X; Wang W; Ye J; Lin Y; Yu B; Zhou L; Zhou Y; Dong H
    Biomed Pharmacother; 2021 Nov; 143():112196. PubMed ID: 34560551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple mechanical complications in ST-segment elevation myocardial infarction with angiographically normal coronary arteries.
    Viveiros Monteiro A; Galrinho A; Moura Branco L; Fragata J; Cruz Ferreira R
    Rev Port Cardiol; 2015 Mar; 34(3):209.e1-3. PubMed ID: 25703652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tirofiban: A Rare Cause of Thrombocytopenia in a Patient Undergoing Percutaneous Coronary Intervention.
    Gulati A; Tiwari A; Shetty V; Nwosu I; Khurana S
    Cureus; 2021 Sep; 13(9):e18217. PubMed ID: 34722029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction.
    Fang CC; Jao YT; Chen Y; Yu CL; Wang SP
    Angiology; 2009; 60(2):192-200. PubMed ID: 18445614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
    Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A patient with acute myocardial infarction with electrocardiogram Aslanger's pattern.
    Liu MH; Li H; Li A; Liu R; Liu HB; Gao LJ; Gu Q; Song L
    BMC Cardiovasc Disord; 2024 Jan; 24(1):3. PubMed ID: 38166569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
    JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unusual ST-t changes in Ebstein's anomaly with occlusion of a nondominant coronary artery.
    Batra R; Nair M; Bhardwaj S; Kaul UA; Arora R
    Indian Heart J; 2002; 54(3):292-4. PubMed ID: 12216927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G; Savonitto S; van't Hof AW; Suryapranata H
    Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kawasaki disease: case report of a diagnostic dilemma and often a missed diagnosis.
    Bin Jawaid Z; Du JL; Iqbal S; Zhang L
    Eur Heart J Case Rep; 2021 Feb; 5(2):ytaa263. PubMed ID: 33738394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diver CE versus Guardwire Plus for thrombectomy in patients with inferior myocardial infarction: a trial of aspiration of thrombus during primary angioplasty for inferior myocardial infarction.
    Yan HB; Wang J; Li N; Zhu XL; Gao H; Ai H; Li X; Ye M; Chi YP; Zhang H
    Chin Med J (Engl); 2007 Apr; 120(7):557-61. PubMed ID: 17442202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Three novel ATG16L1 mutations in a patient with acute myocardial infarction and coronary artery ectasia: A case report.
    Han F; Yan B
    Medicine (Baltimore); 2021 Jan; 100(4):e24497. PubMed ID: 33530273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intracoronary compared with intravenous bolus tirofiban on the microvascular obstruction in patients with STEMI undergoing PCI: a cardiac MR study.
    Ma Q; Ma Y; Wang X; Li S; Yu T; Duan W; Wu J; Wen Z; Jiao Y; Sun Z; Hou Y
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1121-1132. PubMed ID: 32078096
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.